Defective autophagy in multidrug resistant cells may lead to growth inhibition by BH3-mimetic gossypol

Journal of Cellular Physiology

Volumn 228, Issue 7, 2013, Pages 1496-1505

  Ahn, Jun Ho ^a   Jang, Gun Hee ^a   Lee, Michael ^a  

^a SolarLight Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BECLIN 1; BH3 PROTEIN; GOSSYPOL; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BCL 2;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CYCLE ARREST; CELL DEATH; CELL STRAIN 3T3; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DISSOCIATION; DOWN REGULATION; DRUG EFFICACY; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; BIOMIMETIC MATERIALS; CELL LINE, TRANSFORMED; CELL PROLIFERATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; G2 PHASE CELL CYCLE CHECKPOINTS; GENES, BCL-2; GENES, MDR; GENES, RAS; GOSSYPOL; MICE; MITOSIS; NEOPLASMS; NIH 3T3 CELLS; P-GLYCOPROTEIN;

EID: 84875517717     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24305     Document Type: Article

References (47)

1. Ahn J-H, Ahn SK, Lee M. 2002. The role of autophagy in cytotoxicity induced by new oncogenic B-Raf inhibitor UI-152 in v-Ha-ras transformed fibroblasts. Biochem Biophys Res Commun 417: 857-863.
2. Ahn J-H, Kim Y-K, Lee M. 2011. Decreased interaction of Raf-1 with its negative regulator Spry2 as a mechanism for acquired drug resistance. Biomol Ther 19: 174-180.
3. Ahn J-H, Lee M. 2011. Suppression of autophagy sensitizes multidrug resistant cells towards Src tyrosine kinase specific inhibitor PP2. Cancer Lett 310: 188-197.
4. Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. 2008. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 112: 1971-1980.
5. Balci A, Sahin FI, Ekmekci A. 1999. Gossypol induced apoptosis in the human promyelocytic leukemia cell line HL 60. Tohoku J Exp Med 189: 51-57.
6. Benz CC, Keniry MA, Ford JM, Townsend AJ, Cox FW, Palayoor S, Matlin SA, Hait WN, Cowan KH. 1990. Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers. Mol Pharmacol 37: 840-847.
7. Blagosklonny MV. 2007. Mitotic arrest and cell fate: Why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle 6: 70-74.
8. Chen S, Rehman SK, Zhang W, Wen A, Yao L, Zhang J. 2010. Autophagy is a therapeutic target in anticancer drug resistance. Biochim Biophys Acta 1806: 220-229.
9. de Grouw EP, Raaijmakers MH, Boezeman JB, van der Reijden BA, van de Locht LT, de Witte TJ, Jansen JH, Raymakers RA. 2006. Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+ CD38- cells. Leukemia 20: 750-754.
10. Debnath J, Baehrecke EH, Kroemer G. 2005. Does autophagy contribute to cell death? Autophagy 1: e10-e18.
11. Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A. 2009. Life and death partners: Apoptosis, autophagy and the cross-talk between them. Cell Death Differ 16: 966-975.
12. Etxebarria A, Landeta O, Antonsson B, Basañez G. 2008. Regulation of antiapoptotic MCL-1 function by gossypol: mechanistic insights from in vitro reconstituted systems. Biochem Pharmacol 76: 1563-1576.
13. Filippi-Chiela EC, Villodre ES, Zamin LL, Lenz G. 2011. Autophagy interplay with apoptosis and cell cycle regulation in the growth inhibiting effect of resveratrol in glioma cells. PLoS ONE 6: e20849.
14. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. 2006. Clongenic assay of cells in vitro. Nat Protoc 1: 2315-2319.
15. Gao P, Bauvy C, Souquere S, Tonelli G, Liu L, Zhu Y, Qiao Z, Bakula D, Proikas-Cezanne T, Pierron G, Codogno P, Chen Q, Mehrpour M. 2010. The BH3-mimetic gossypol induces both beclin 1-dependent and beclin 1-independent cytoprotective autophagy in cancer cells. J Biol Chem 285: 25570-25581.
16. Gartel AL, Tyner AL. 2002. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1: 639-649.
17. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K, Bursch W, Schulte-Hermann R. 1995. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: A cautionary note. Hepatology 21: 1465-1468.
18. Han J, Kim S, Yang JH, Nam SJ, Lee JE. 2012. TPA-induced p21 expression augments G2/M arrest through a p53-independent mechanism in human breast cancer cells. Oncol Rep 27: 517-522.
19. 31P nuclear magnetic resonance and toxicity studies. Cancer Res 50: 6936-6943.
20. Kim Y-K, Ahn J-H, Lee M. 2012. Src family kinase inhibitor PP2 induces LC3 conversion in a manner that is uncoupled from autophagy and increases apoptosis in multidrug-resistant cells. Biomol Ther 20: 393-398.
21. Kondo Y, Kanzawa T, Sawaya R, Kondo S. 2005. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5: 726-734.
22. Kong D, Ma S, Liang B, Yi H, Zhao Y, Xin R, Cui L, Jia L, Liu X, Liu X. 2012. The different regulatory effects of p53 status on multidrug resistance are determined by autophagy in ovarian cancer cells. Biomed Pharmacother 66: 271-278.
23. Lee M, Ahn J-H, Eum K-H. 2009. The differences in biological properties between parental and v-Ha-ras transformed NIH3T3 cells. Cancer Res Treat 41: 93-99.
24. Lei X, Chen Y, Du G, Yu W, Wang X, Qu H, Xia B, He H, Mao J, Zong W, Liao X, Mehrpour M, Hao X, Chen Q. 2006. Gossypol induces Bax/Bak-independent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2. FASEB J 20: 2147-2149.
25. Levine B, Yuan J. 2005. Autophagy in cell death: An innocent convict? J Clin Invest 115: 2679-2688.
26. Lian J, Wu X, He F, Karnak D, Tang W, Meng Y, Xiang D, Ji M, Lawrence TS, Xu L. 2011. A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell Death Differ 18: 60-71.
27. Liu GZ. 1981. Clinical study of gossypol as a male contraceptive. Reproduction 5: 189-193.
28. Liu S, Kulp SK, Sugimoto Y, Jiang J, Chang HL, Dowd MK, Wan P, Lin YC. 2002. The (-)-enantiomer of gossypol possesses higher anticancer potency than racemic gossypol in human breast cancer. Anticancer Res 22: 33-38.
29. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
30. Marcus AI, Peters U, Thomas SL, Garrett S, Zelnak A, Kapoor TM, Giannakakou P. 2005. Mitotic kinesin inhibitors induce mitotic arrest and cell death in taxol-resistant and -sensitive cancer cells. J Biol Chem 280: 11569-11577.
31. Meijer AJ, Codogno P. 2009. Autophagy: regulation and role in disease. Crit Rev Clin Lab Sci 46: 210-240.
32. Meric-Bernstam F, Gonzalez-Angulo AM. 2009. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27: 2278-2287.
33. Moretti L, Yang ES, Kim KW, Lu B. 2007. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy. Drug Resist Updat 10: 135-143.
34. Oliver CL, Bauer JA, Wolter KG, Ubell ML, Narayan A, O'Connell KM, Fisher SG, Wang S, Wu X, Ji M, Carey TE, Bradford CR. 2004. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res 10: 7757-7763.
35. Oliver CL, Miranda MB, Shangary S, Land S, Wang S, Johnson DE. 2005. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-XL-mediated apoptosis resistance. Mol Cancer Ther 4: 23-31.
36. Patel MP, Masood A, Patel PS, Chanan-Khan AA. 2009. Targeting the Bcl-2. Curr Opin Oncol 21: 516-523.
37. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B. 2005. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122: 927-939.
38. Priyadarshi A, Roy A, Kim KS, Kim EE, Hwang KY. 2010. Structural insights into mouse anti-apoptotic Bcl-xl reveal affinity for Beclin 1 and gossypol. Biochem Biophys Res Commun 394: 515-521.
39. Shepu X, Shudong Z, Shuyun S, Yanwan W, Yi L, Zenghua Z, Xixin M. 1980. Antispermatogenic effect of gossypol on the germinal epithelium of the rat testes. A cytological, autoradiographical and ultrastructural observation. Sci Sin 23: 642-657.
40. Shidaifat F, Canatan H, Kulp SK, Sugimoto Y, Zhang Y, Brueggemeier RW, Somers WJ, Chang WY, Wang HC, Lin YC. 1997. Gossypol arrests human benign prostatic hyperplastic cell growth at G0/G1 phase of the cell cycle. Anticancer Res 17: 1003-1009.
41. Stähelin BJ, Marti U, Solioz M, Zimmermann H, Reichen J. 1998. False positive staining in the TUNEL assay to detect apoptosis in liver and intestine is caused by endogenous nucleases and inhibited by diethyl pyrocarbonate. Mol Pathol 51: 204-208.
42. Toyoshima H, Huter T. 1994. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78: 67-74.
43. Tuszynski GP, Cossu G. 1984. Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines. Cancer Res 44: 768-771.
44. Xu L, Yang D, Wang S, Tang W, Liu M, Davis M, Chen J, Rae JM, Lawrence T, Lippman ME. 2005. (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther 4: 197-205.
45. Ye W, Chang HL, Wang LS, Huang YW, Shu S, Dowd MK, Wan PJ, Sugimoto Y, Lin YC. 2007. Modulation of multidrug resistance gene expression in human breast cancer cells by (-)-gossypol-enriched cottonseed oil. Anticancer Res 27: 107-116.
46. Zhang M, Liu H, Guo R, Ling Y, Wu X, Li B, Roller PP, Wang S, Yang D. 2003. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol 66: 93-103.
47. Zhang M, Liu H, Tian Z, Huang J, Remo M, Li QQ. 2007. Differential growth inhibition and induction of apoptosis by gossypol between HCT116 and HCT116/Bax(-/-) colorectal cancer cells. Clin Exp Pharmacol Physiol 34: 230-237.